Current Edition

bio

Bluebird Bio has ‘doubts’ about continuing to do business through 2022, announces CFO resignation

With two of its prized gene therapies on clinical hold and another, Zynteglo, pulled from the market in Europe seven months ago after it was …

Continue Reading →
Ayurvedic

Clinical Evaluation of Ayurvedic Interventions: Current Scenario in Indian Market

Ayurveda, the science of life, has evolved into a comprehensive system of healthcare based on high-quality scientific experiments with a sound and reproducible evidence base …

Continue Reading →
antibiotic resistance

Antibiotic resistance: Pherecydes Pharma raises €8.7M ($10.3M)

Pherecydes Pharma, a biotechnology company specialized in the research and development of anti-infective therapies based on the use of bacteriophages, today announces that it has …

Continue Reading →
Crohn's disease

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …

Continue Reading →